Literature DB >> 35059259

Glycated albumin (GA) and the GA/HbA1c ratio are higher in diabetic patients positive for insulin antibodies with high binding capacity and low affinity.

Takehito Takeuchi1, Yushi Hirota1, Yasushi Nakagawa1, Atsuko Matsuoka1, Tetsushi Hamaguchi1, Yuko Okada1, Kazuhiko Sakaguchi1, Wataru Ogawa1, Masafumi Koga2.   

Abstract

Patients with diabetes mellitus having insulin antibodies (InsAb) with properties of high binding capacity and low affinity, which are observed in insulin autoimmune syndrome (IAS), are known to have greater plasma glucose fluctuations. Glycated albumin (GA) and the GA/HbA1c ratio have been demonstrated to reflect plasma glucose fluctuations. Hence, we hypothesized that GA or the GA/HbA1c ratio in diabetic patients having InsAb with properties of high binding capacity and low affinity may be higher than those in InsAb-negative diabetic patients, and we verified this hypothesis. Subjects were 12 diabetic patients who had InsAb noted while being treated with insulin and were subjected to Scatchard analysis and whose InsAb had properties similar to those of patients with IAS (affinity constant K1 < 0.24 × 1/10-8 M, number of binding sites R1 ≥ 11.5 × 10-8 M) [four cases of type 1 diabetes (T1D) and eight cases of type 2 diabetes (T2D)]. The control group consisted of T1D and T2D cases matched to the T1D and T2D cases, respectively, according to sex, age, BMI, and HbA1c. GA and the GA/HbA1c ratio were compared between both groups. GA and the GA/HbA1c ratio in InsAb-positive patients was significantly higher than that in the control group for both T1D and T2D patients. Diabetic patients having InsAb with properties of high binding capacity and low affinity had higher GA and the GA/HbA1c ratio than those of InsAb-negative patients. Greater plasma glucose fluctuations were suggested in InsAb-positive diabetic patients. © The Japan Diabetes Society 2021.

Entities:  

Keywords:  Diabetes; Glycated albumin; HbA1c; Insulin antibodies; Insulin autoimmune syndrome

Year:  2021        PMID: 35059259      PMCID: PMC8733108          DOI: 10.1007/s13340-021-00528-z

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  28 in total

1.  Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody--a case report.

Authors:  Arata Itoh; Yoshifumi Saisho; Masanori Mitsuishi; Yoichi Oikawa; Toshihide Kawai; Masami Tanaka; Akira Shimada; Hiroshi Itoh
Journal:  Diabetes Res Clin Pract       Date:  2011-07-02       Impact factor: 5.602

2.  Methimazole and insulin autoimmune syndrome with hypoglycemia.

Authors:  Y Hirata
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

3.  Alternative Measures of Hyperglycemia and Risk of Alzheimer's Disease in the Community: The Hisayama Study.

Authors:  Naoko Mukai; Tomoyuki Ohara; Jun Hata; Yoichiro Hirakawa; Daigo Yoshida; Hiro Kishimoto; Masafumi Koga; Udai Nakamura; Takanari Kitazono; Yutaka Kiyohara; Toshiharu Ninomiya
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

4.  Acute liver dysfunction complicated with uncontrollable glycemia due to insulin antibody: successful treatment with glucocorticoid and lispro insulin.

Authors:  Munehiro Honda; Yumi Kawashima; Hiroko Kawamura; Hirotoshi Fujikawa; Kentaro Kikuchi; Hiroshi Ohashi; Yasumichi Mori; Hiroshi Miyakawa; Miyuki Ishibashi
Journal:  Intern Med       Date:  2006-12-01       Impact factor: 1.271

5.  Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report.

Authors:  J T Lahtela; M Knip; R Paul; J Antonen; J Salmi
Journal:  Diabetes Care       Date:  1997-01       Impact factor: 19.112

6.  Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes.

Authors:  Kazutomi Yoshiuchi; Munehide Matsuhisa; Naoto Katakami; Yoshihisa Nakatani; Kenya Sakamoto; Takaaki Matsuoka; Yutaka Umayahara; Keisuke Kosugi; Hideaki Kaneto; Yoshimitsu Yamasaki; Masatsugu Hori
Journal:  Endocr J       Date:  2008-04-30       Impact factor: 2.349

7.  Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF.

Authors:  T Segal; Ea Webb; R Viner; C Pusey; G Wild; J Allgrove
Journal:  Pediatr Diabetes       Date:  2008-06       Impact factor: 4.866

8.  New indices for predicting glycaemic variability.

Authors:  Akifumi Ogawa; Akinori Hayashi; Eriko Kishihara; Sonomi Yoshino; Akihiro Takeuchi; Masayoshi Shichiri
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

Review 9.  Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients.

Authors:  Xiaolei Hu; Fengling Chen
Journal:  Endocr Connect       Date:  2017-12-12       Impact factor: 3.335

10.  Repeated hypoglycemia caused by the overproduction of anti-insulin antibodies and isolated ACTH deficiency in a type 2 diabetic patient receiving insulin therapy.

Authors:  Masanori Yoshida; Miho Murakami; Koichiro Ogawa; Masato Asai; Misaki Miyata; Harumi Maeda; Yutaka Oiso
Journal:  Diabetes Care       Date:  2013-02       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.